• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Latest News

Omalizumab increases reaction threshold for multiple common food allergies | Image Credit: © Yulia - © Yulia - stock.adobe.com.
Omalizumab increases reaction threshold for multiple common food allergies

February 26th 2024

Omalizumab was approved by the FDA on February 16, 2024 as the first and only FDA-approved medicine to reduce allergic reactions in patients with 1 or more food allergies.

Contemporary Pediatrics Week in Review | Image Credit: © Artur - © Artur - stock.adobe.com.
Week in review: Neffy repeat dose study data, fostering healthy eating habits

February 26th 2024

Thomas Casale, MD
Neffy for patients with anaphylactic symptoms after oral food challenge

February 23rd 2024

Clinician quiz: AAP clinical practice guideline for treatment of children with obesity | Image Credit: © Daqota - © Daqota - stock.adobe.com.
Clinician quiz: AAP clinical practice guideline for treatment of children with obesity

February 23rd 2024

Sarina Tanimoto, MD, MBA, chief medical officer, ARS Pharma | Image Credit: ARS Pharma
Neffy pharmacokinetic profiles compared to epinephrine injections

February 23rd 2024

Latest Videos
Podcasts

All News

© 2024 MJH Life Sciences

All rights reserved.